Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company reported a revenue of 1.21 billion yuan for 2024, representing a year-on-year increase of 35.6%, and a net profit of 109 million yuan, up 23.8% [2][3] - The company is focusing on both international market dynamics and expanding its domestic market presence, with significant growth potential in China's fitness equipment market [4] - The company is actively pursuing a smart transformation by integrating AI technology into its product offerings, which includes 28 series of fitness equipment [5] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 1.21 billion yuan, with a year-on-year growth of 35.6%, and a net profit of 109 million yuan, reflecting a growth of 23.8% [2][3] - For Q1 2025, the revenue was 291 million yuan, showing a year-on-year increase of 21.9%, with a net profit of 14 million yuan, up 2.19% [2] Business Growth - The traditional business segment is experiencing steady growth, with commercial products accounting for 87.7% of revenue and overseas sales making up 78.7% [3] - The company is enhancing its OEM/ODM product offerings and has successfully launched over 10 new products [3] Market Potential - The domestic fitness market is expected to grow significantly, with China's fitness penetration rate at 5.37% as of 2023, compared to higher rates in the US, UK, and Germany [4] - The company aims to mitigate risks associated with international markets by tapping into the vast potential of the domestic market [4] Strategic Initiatives - The company is deepening its application of AI technology to create smart fitness solutions, positioning itself for future growth in the AI glasses sector [5] - The report forecasts revenue growth for 2025-2027 to be 1.31 billion, 1.64 billion, and 1.89 billion yuan, respectively, with net profits projected at 103 million, 144 million, and 181 million yuan [6][8]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company has shown strong revenue growth, achieving 1.214 billion yuan in 2024, a year-on-year increase of 35.6%, and a net profit of 109 million yuan, up 23.8% year-on-year [2][3] - The company is experiencing a transformation with a focus on its own brand, which is expected to continue driving high growth in 2025 [2] - The company’s profitability faced temporary pressure due to increased depreciation costs, but operational efficiency is expected to improve in the coming quarters [3] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 1.214 billion yuan, with a year-on-year growth rate of 35.6% [4] - The net profit attributable to the parent company for 2024 was 109 million yuan, reflecting a year-on-year increase of 23.8% [4] - For Q1 2025, the company reported revenue of 291 million yuan, a year-on-year increase of 21.9%, and a net profit of 14 million yuan, which is a slight increase of 2.2% year-on-year [3] Revenue Breakdown - In 2024, domestic sales generated 259 million yuan (up 7.5% year-on-year), while overseas sales reached 955 million yuan (up 45.9% year-on-year) [2] - The gross margin for domestic sales was 33.0% (up 5.4 percentage points), while for overseas sales it was 31.4% (down 2.0 percentage points) [2] Profitability and Cost Management - The gross margin for Q1 2025 was 25.4%, down 2.8 percentage points year-on-year, while the net profit margin was 4.9%, down 0.9 percentage points year-on-year [3] - The company maintained a strong cost control with a total expense ratio of 19.20% in Q1 2025, which is a decrease of 1.1 percentage points year-on-year [3] Future Projections - The company’s net profit is projected to reach 125 million yuan in 2025, 143 million yuan in 2026, and 164 million yuan in 2027, with corresponding P/E ratios of 23.76X, 20.76X, and 18.08X respectively [4]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company has shown strong revenue growth, achieving 1.214 billion yuan in 2024, a year-on-year increase of 35.6%, and a net profit of 109 million yuan, up 23.8% year-on-year [2][3] - The company is experiencing a transformation with a focus on its own brand, which is expected to continue driving high growth in the coming years [2][3] - The company is managing costs effectively, with a decrease in expense ratios, which is expected to improve profitability as production efficiency increases [3] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 1.214 billion yuan, with a year-on-year growth rate of 35.6% [4] - The net profit attributable to the parent company was 109 million yuan, reflecting a year-on-year increase of 23.8% [4] - For Q1 2025, the company reported revenue of 291 million yuan, a year-on-year increase of 21.9%, and a net profit of 14 million yuan, up 2.2% year-on-year [2][3] Revenue Breakdown - Domestic sales reached 259 million yuan, growing by 7.5% year-on-year, while overseas sales were 955 million yuan, up 45.9% year-on-year [2] - The gross margin for domestic sales was 33.0%, while for overseas sales it was 31.4% [2] Profitability and Cost Management - The gross margin for Q1 2025 was 25.4%, down 2.8 percentage points year-on-year, while the net profit margin was 4.9%, down 0.9 percentage points year-on-year [3] - The company has maintained a strong control over expenses, with a total expense ratio of 19.20%, down 1.1 percentage points year-on-year [3] Future Projections - The company is projected to achieve net profits of 125 million yuan, 143 million yuan, and 164 million yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 23.76X, 20.76X, and 18.08X [4][3]

Core Viewpoint - The company, Qingdao Inpace Health Technology Co., Ltd., has announced the reappointment of Heshin Accounting Firm as its auditor for the year 2025, ensuring the continuity of its auditing services and compliance with regulatory requirements [9][10][19]. Financial Data - The first quarter report for the company has not been audited [8]. - The company has repurchased 1,256,700 shares, accounting for 0.85% of the total share capital as of the reporting period [5]. Shareholder Information - The company has confirmed that there are no changes in the major shareholders and their shareholding status compared to the previous period [6]. Audit Firm Information - Heshin Accounting Firm has been selected for reappointment, with an audit fee of 850,000 yuan and an internal control audit fee of 280,000 yuan, remaining the same as the previous year [10][17]. - The firm has a total of 45 partners and 254 registered accountants, with 139 of them having signed audit reports for securities services [11]. - The firm has not faced any criminal penalties or disciplinary actions in the last three years [13][15]. Audit Committee and Board Decisions - The audit committee has reviewed and approved the reappointment of Heshin Accounting Firm, emphasizing its qualifications and independence [18]. - The board of directors unanimously approved the proposal to reappoint the audit firm, which will be subject to shareholder approval [19].

2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3.第一季度报告是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ （二） 非经常性损益项目和金额 √适用 □不适用 单位：元 ■ 其他符合非经常性损益定义的损益项目的具体情况 □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 √不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性 损益项目界定为经常性损益的项目 ...

青岛英派斯健康科技股份有限公司 非经营性资金占用及其他关联资金往来情况的 专项说明 二〇二五年四月二十五日 | 目 | 录 | 页 | 码 | | --- | --- | --- | --- | | 一、非经营性资金占用及其他关联资金往来情况的专项说明 | | 1-2 | | | 二、非经营性资金占用及其他关联资金往来情况汇总表 | | 3 | | 和信专字（2025）第 000259 号 和信会计师事务所（特殊普通合伙） 青岛英派斯健康科技股份有限公司 非经营性资金占用及其他关联资金往来情况的 专项说明 和信专字（2025）第 000259 号 青岛英派斯健康科技股份有限公司全体股东： 我们接受委托，审计了青岛英派斯健康科技股份有限公司（以下简称"英派斯"）2024 年度财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公 司利润表、合并及公司现金流量表、合并及公司所有者权益变动表以及相关财务报表附注， 并于 2025 年 4 月 25 日出具了和信审字（2025）第 000689 号标准无保留意见审计报告。 根据中国证券监督管理委员会等四部委联合发布的《上市公司 ...

青岛英派斯健康科技股份有限公司 青岛英派斯健康科技股份有限公司全体股东： 一、审计意见 二○二五年四月二十五日 青岛英派斯健康科技股份有限公司 报告正文 审 计 报 告 和信审字（2025）第 000689 号 审计报告 和信审字（2025）第 000689 号 | 目 录 | 页 码 | | --- | --- | | 一、审计报告 | 1-8 | | 二、已审财务报表及附注 | | | 1、合并及公司资产负债表 | 9-12 | | 2、合并及公司利润表 | 13-14 | | 3、合并及公司现金流量表 | 15-16 | | 4、合并及公司所有者权益变动表 | 17-20 | | 5、财务报表附注 | 21-122 | 和信会计师事务所（特殊普通合伙） 我们审计了青岛英派斯健康科技股份有限公司（以下简称"英派斯"、"公司"） 财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并 及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及相关财 务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了英派斯 2024 年 1 ...

太平洋证券股份有限公司 关于青岛英派斯健康科技股份有限公司 2024 年度募集资金存放 与实际使用情况的专项核查意见 太平洋证券股份有限公司（以下简称"太平洋证券"或"保荐机构"）作为 青岛英派斯健康科技股份有限公司（以下简称"英派斯"或"公司"）承接持续 督导的保荐机构，根据《证券发行上市保荐业务管理办法》、《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》、《深 圳证券交易所股票上市规则（2024 年修订）》、《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作（2023 年 12 月修订）》等有关规定， 对英派斯 2024 年度募集资金存放与使用情况进行了审慎核查，核查情况及核查 意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 1、首次公开发行股票 2024 年度募集资金专户使用情况及 2024 年 12 月 31 日余额如下： | 2023年12月31日募集资金余额 | 1,732,423.55 | | --- | --- | | 加：期初闲置募集资金购买理财产品本金 | | | 加：赎回暂时闲置募集资金购买理财产品 ...

青岛英派斯健康科技股份有限公司 内部控制审计报告 和信审字（2025）第 000713 号 和信会计师事务所（特殊普通合伙） 二〇二五年四月二十五日 青岛英派斯健康科技股份有限公司 报告正文 内部控制审计报告 和信审字（2025）第 000713 号 青岛英派斯健康科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了青岛英派斯健康科技股份有限公司（以下简称"英派斯"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，英派斯于 2024 年 12 月 31 日按照《企业内部控制基本规范》和相 关规定在所有重大方面保持了有效的财务报告内部控制。 （以下无正文） 和信会计师事务所（特殊普通合伙） 1 青岛英派斯健康科技股份有限公司 报告正文 按照《企业内部控制基本 ...

太平洋证券股份有限公司关于 青岛英派斯健康科技股份有限公司 2024 年度保荐工作报告 | 保荐机构名称：太平洋证券股份有限公司 | 被保荐公司简称：英派斯（002899.SZ） | | --- | --- | | 保荐代表人姓名：欧阳凌 | 联系电话：010-88321518 | | 保荐代表人姓名：张兴林 | 联系电话：010-88321821 | 二、保荐机构发现公司存在的问题及采取的措施 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 1.信息披露 | 无 | 不适用 | | 2.公司内部制度的建立和执行 | 无 | 不适用 | | 3."三会"运作 | 无 | 不适用 | | 4.控股股东及实际控制人变动 | 无 | 不适用 | | 5.募集资金存放及使用 | 无 | 不适用 | | 6.关联交易 | 无 | 不适用 | | 7.对外担保 | 无 | 不适用 | | 8.购买、出售资产 | 无 | 不适用 | 2 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 9.其他业务类别重要事项（包括对外投资、风险投 | 无 ...